Quantcast
Home > Quotes > CGIX
CGIX

Cancer Genetics, Inc. Common Stock (CGIX) Quote & Summary Data

$0.2305
*  
0.0014
0.61%
Get CGIX Alerts
*Delayed - data as of Apr. 23, 2019 12:47 ET  -  Find a broker to begin trading CGIX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CGIX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.2302 / $ 0.232
1 Year Target
4.5
Today's High / Low
$ 0.2399 / $ 0.225
Share Volume
358,892
50 Day Avg. Daily Volume
1,320,489
Previous Close
$ 0.2291
52 Week High / Low
$ 1.30 / $ 0.20
Market Cap
12,971,669
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.89

Intraday Chart

Shares Traded

Share Volume:
358,892
50 Day Avg. Daily Volume:
1,320,489

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.74

Trading Range

The current last sale of $0.2305 is 15.25% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.2399 $ 1.30
 Low: $ 0.225 $ 0.20

Company Description (as filed with the SEC)

We are an emerging leader in enabling precision medicine in oncology by providing multi-disciplinary diagnostic and data solutions, facilitating individualized therapies through our diagnostic tests, services and molecular markers. We develop, commercialize and provide molecular- and biomarker-based tests and services, including proprietary preclinical oncology and immuno-oncology services, that enable biotech and pharmaceutical companies engaged in oncology and immuno-oncology trials to better select candidate populations and reduce adverse drug reactions by providing information regarding genomic and molecular factors influencing subject responses to therapeutics. Through our clinical services, we enable physicians to personalize the clinical management of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment.  ... More ...  



Risk Grade

Where does CGIX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.225
Open Date:
Apr. 23, 2019
Close Price:
$ 0.2291
Close Date:
Apr. 22, 2019


Consensus Recommendation

Analyst Info